Impact Biomedical Inc. (NASDAQ: IBO) reported insider sales by its chief financial officer, Todd D. Macko, who disposed of 45,000 shares of common stock in two separate transactions recorded on March 25 and March 27, 2026, according to a Form 4 filed with the Securities and Exchange Commission.
The combined proceeds from those sales amounted to $25,330. Reported prices for the transactions ranged from $0.5615 to $0.6008 per share. Following the two dispositions, Macko is listed as directly owning 155,122 shares of the company.
At the time of the filing the stock was trading at $0.59 and year-to-date performance stood at a gain of 15.92 percent. InvestingPro analysis included with the filing indicates that, on a Fair Value basis, Impact Biomedical appears overvalued at current market levels.
InvestingPro Tips accompanying the disclosure emphasize the firm’s recent market momentum while also flagging ongoing profitability challenges. The note references eight additional exclusive tips that are available to subscribers who follow InvestingPro content.
Separately, ProPicks AI is described as a tool that evaluates IBO along with thousands of other companies each month, using more than 100 financial metrics. The description states the AI identifies stocks based on fundamentals, momentum, and valuation without bias, and cites notable past winners of the approach. The text also invites readers to check whether IBO is featured in any active ProPicks AI strategies or if there are alternative opportunities in the same space.
Transaction details
- Insider: Todd D. Macko, Chief Financial Officer
- Shares sold: 45,000 across two transactions
- Transaction dates: March 25 and March 27, 2026
- Price range: $0.5615 to $0.6008
- Total proceeds: $25,330
- Post-sale direct ownership: 155,122 shares
Market context
The stock quoted at $0.59 at the time of reporting and was up 15.92 percent year-to-date. InvestingPro’s Fair Value assessment is cited as indicating the company appears overvalued at that market price. InvestingPro Tips additionally highlight the contrast between recent momentum and the company’s profitability hurdles, and refer readers to more proprietary tips available to subscribers.
What this means
This disclosure records routine insider selling activity and provides readers with the specific mechanics of the trades. The filing also pairs that transactional detail with third-party analysis on valuation and operations, enabling market participants to view the sale in the context of both insider holdings and an independent assessment of valuation and profitability.